Tiziana生命科学公司（Tiziana Life Sciences PLC）今日宣布，其鼻内给药Foralumab治疗多发性硬化症的2a期Inform-MS临床试验已迎来里程碑时刻——最后一位受试者圆满完成末次访视。这一进展标志着该试验的患者随访阶段正式画上句号，为后续的数据揭盲与分析铺平了道路。随着临床研究的这一关键节点落地，业界目光正聚焦于这家生物技术公司即将公布的试验结果。Foralumab作为一种全人源抗CD3单克隆抗体，经鼻内途径给药后，有望通过调节免疫反应来缓解多发性硬化症相关的神经炎症。此番末次访视的完成，不仅意味着研究团队已收集齐所有预设的临床数据点，更代表着整个试验流程进入收官阶段。接下来，Tiziana将着手对庞大的数据进行系统性整理与统计分析，以评估该候选药物的安全性、耐受性及初步疗效信号。市场人士普遍认为，这一进展若能顺利转化为积极数据，或将重塑多发性硬化症治疗领域的竞争格局。Tiziana管理层此前曾表示，Inform-MS试验旨在探索一种更为便捷、侵入性更低的治疗新模式，其最终结果备受投资者与学术界期待。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.